A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: A new approaches to neuroblastoma therapy (NANT) study
| Autor: | Heike E. Daldrup-Link, Julie R. Park, Yves A. DeClerck, Andrej Skerjanec, Hollie A. Jackson, Judith G. Villablanca, Randy Hawkins, Susan M. Blaney, Howard M. Katzenstein, Tasnim Ara, Araz Marachelian, Heidi V. Russell, Katherine K. Matthay, Susan Groshen |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Oncology
medicine.medical_specialty Cyclophosphamide business.industry medicine.medical_treatment Hematology Bisphosphonate Pharmacology medicine.disease Clinical trial Zoledronic acid Refractory Neuroblastoma Internal medicine Pediatrics Perinatology and Child Health medicine Dosing business Survival analysis medicine.drug |
| Zdroj: | Pediatric Blood & Cancer. 57:275-282 |
| ISSN: | 1545-5009 |
| DOI: | 10.1002/pbc.22821 |
| Popis: | Background Zoledronic acid, a bisphosphonate, delays progression of bone metastases in adult malignancies. Bone is a common metastatic site of advanced neuroblastoma. We previously reported efficacy of zoledronic acid in a murine model of neuroblastoma bone invasion prompting this Phase I trial of zoledronic acid with cyclophosphamide in children with neuroblastoma and bone metastases. The primary objective was to determine recommended dosing of zoledronic acid for future trials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text